A Self-Assembling and Disassembling (SADA) Bispecific Antibody (BsAb) Platform for Curative Two-step Pretargeted Radioimmunotherapy
暂无分享,去创建一个
S. Larson | C. Rudin | M. McDevitt | N. Cheung | D. Veach | O. Ouerfelli | P. Zanzonico | Mahiuddin Ahmed | S. Monette | S. Cheal | E. K. Fung | Mitesh Patel | Hong-fen Guo | A. Michel | Brian H. Santich | Guangbin Yang | Daniela Burnes Vargas | A. Malik | B. Santich
[1] Kazuro Furukawa,et al. Disruption of GM2/GD2 synthase gene resulted in overt expression of 9-O-acetyl GD3 irrespective of Tis211 , 2008, Journal of neurochemistry.
[2] G W Beresford,et al. Pharmacokinetics and biodistribution of engineered single-chain antibody constructs of MAb CC49 in colon carcinoma xenografts. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[3] Michael M. Schmidt,et al. A modeling analysis of the effects of molecular size and binding affinity on tumor targeting , 2009, Molecular Cancer Therapeutics.
[4] S. Larson,et al. Theranostic pretargeted radioimmunotherapy of colorectal cancer xenografts in mice using picomolar affinity 86Y- or 177Lu-DOTA-Bn binding scFv C825/GPA33 IgG bispecific immunoconjugates , 2016, European Journal of Nuclear Medicine and Molecular Imaging.
[5] Andreas Plückthun,et al. PEGylation and Multimerization of the Anti-p185HER-2 Single Chain Fv Fragment 4D5 , 2006, Journal of Biological Chemistry.
[6] J. Bertho,et al. Radiation-Induced Increase in Plasma Flt3 Ligand Concentration in Mice: Evidence for the Implication of Several Cell Types , 2005, Radiation research.
[7] Jason S. Lewis,et al. Establishment of the In Vivo Efficacy of Pretargeted Radioimmunotherapy Utilizing Inverse Electron Demand Diels-Alder Click Chemistry , 2016, Molecular Cancer Therapeutics.
[8] A. Oronsky,et al. What's New in SCLC? A Review , 2017, Neoplasia.
[9] W. Mcbride,et al. Multifunctional Antibodies by the Dock-and-Lock Method for Improved Cancer Imaging and Therapy by Pretargeting , 2007, Journal of Nuclear Medicine.
[10] A. Lin,et al. Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials , 2019, Science Translational Medicine.
[11] J. Frangioni,et al. Biodistribution and Clearance of Small Molecule Hapten Chelates for Pretargeted Radioimmunotherapy , 2011, Molecular Imaging and Biology.
[12] S. Larson,et al. Radioimmunotherapy of human tumours , 2015, Nature Reviews Cancer.
[13] J. Soria,et al. Antibody–Drug Conjugates: Future Directions in Clinical and Translational Strategies to Improve the Therapeutic Index , 2019, Clinical Cancer Research.
[14] M. Huse,et al. Interdomain spacing and spatial configuration drive the potency of IgG-[L]-scFv T cell bispecific antibodies , 2020, Science Translational Medicine.
[15] N. Cheung,et al. Human derived dimerization tag enhances tumor killing potency of a T-cell engaging bispecific antibody , 2015, Oncoimmunology.
[16] A. Giusti,et al. 177Lu-DOTA-HH1, a Novel Anti-CD37 Radio-Immunoconjugate: A Study of Toxicity in Nude Mice , 2014, PLoS ONE.
[17] D. Goldenberg,et al. Red marrow radiation dose adjustment using plasma FLT3-L cytokine levels: improved correlations between hematologic toxicity and bone marrow dose for radioimmunotherapy patients. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[18] M. Huse,et al. Successful engineering of a highly potent single-chain variable-fragment (scFv) bispecific antibody to target disialoganglioside (GD2) positive tumors , 2016, Oncoimmunology.
[19] S. Larson,et al. Alpha radioimmunotherapy using 225Ac-proteus-DOTA for solid tumors - safety at curative doses , 2020, Theranostics.
[20] N. Cheung,et al. Complete tumor ablation with iodine 131-radiolabeled disialoganglioside GD2-specific monoclonal antibody against human neuroblastoma xenografted in nude mice. , 1986, Journal of the National Cancer Institute.
[21] M. Huse,et al. Retargeting T Cells to GD2 Pentasaccharide on Human Tumors Using Bispecific Humanized Antibody , 2014, Cancer Immunology Research.
[22] D. Scheinberg,et al. Pharmacokinetics, dosimetry, and toxicity of the targetable atomic generator, 225Ac-HuM195, in nonhuman primates. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[23] Jason S. Lewis,et al. Leveraging Bioorthogonal Click Chemistry to Improve 225Ac-Radioimmunotherapy of Pancreatic Ductal Adenocarcinoma , 2018, Clinical Cancer Research.
[24] G. N. Cox,et al. Enhanced circulating half-life and antitumor activity of a site-specific pegylated interferon-alpha protein therapeutic. , 2008, Bioconjugate chemistry.
[25] S. Larson,et al. A N-acetylgalactosamino Dendron-Clearing Agent for High-Therapeutic Index DOTA-Hapten Pretargeted Radioimmunotherapy. , 2019, Bioconjugate chemistry.
[26] K Dane Wittrup,et al. Engineering an antibody with picomolar affinity to DOTA chelates of multiple radionuclides for pretargeted radioimmunotherapy and imaging. , 2011, Nuclear medicine and biology.
[27] S. Larson,et al. Preclinical Evaluation of Multistep Targeting of Diasialoganglioside GD2 Using an IgG-scFv Bispecific Antibody with High Affinity for GD2 and DOTA Metal Complex , 2014, Molecular Cancer Therapeutics.
[28] Giovanni Parmigiani,et al. A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. , 2009, Cancer research.
[29] N. Cheung,et al. Disialoganglioside GD2 as a therapeutic target for human diseases , 2015, Expert opinion on therapeutic targets.
[30] Hong-fen Guo,et al. Humanizing murine IgG3 anti-GD2 antibody m3F8 substantially improves antibody-dependent cell-mediated cytotoxicity while retaining targeting in vivo , 2012, Oncoimmunology.
[31] S. Larson,et al. Single-chain Fv-streptavidin substantially improved therapeutic index in multistep targeting directed at disialoganglioside GD2. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[32] Damon L. Meyer,et al. Comparison of immunoscintigraphy, efficacy, and toxicity of conventional and pretargeted radioimmunotherapy in CD20-expressing human lymphoma xenografts. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[33] R. Weinberg,et al. A Perspective on Cancer Cell Metastasis , 2011, Science.
[34] D. Scheinberg,et al. Renal tubulointerstitial changes after internal irradiation with alpha-particle-emitting actinium daughters. , 2005, Journal of the American Society of Nephrology : JASN.
[35] J. Young,et al. Relationship of effective molecular size to systemic clearance in rats of recombinant interleukin-2 chemically modified with water-soluble polymers. , 1988, The Journal of biological chemistry.